Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 3105 - 3112 of 12140 results

Climate Disclosures?!

July 14, 2021| News

Bipartisan VALID Act Re-Introduced in Congress: Is Diagnostics Reform on the Horizon?

July 13, 2021| Blog| Viewpoint

NYC Businesses: Do you have your “biometric identifier collection” notice up?

July 12, 2021| Blog| Viewpoint

Massachusetts Executive Order Permitting Massachusetts Public Companies to Hold Virtual-Only Shareholder Meetings to Expire

July 12, 2021| Advisory| Viewpoint

Busy Week for the FTC Shows Aspirations of and Limitations on Chair Khan’s Enforcement Agenda

July 9, 2021| Blog| Viewpoint

President Biden’s Competition Executive Order’s “Encouragement” to the FTC and DOJ Antitrust Division

July 9, 2021| Alert| Viewpoint

Apple Trial Spotlights U.K. Ban Potential in Global Patent Fights

July 8, 2021| News

NY HERO Act Standards & Template Policies Released – Employer Action Required

July 8, 2021| Blog| Viewpoint

News & Press Releases

Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber

September 15, 2025

Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering

September 12, 2025

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement

September 12, 2025

Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.

View all News and Press Releases